June 24, 2026
New Therapy Combines Wnt Activation and VEGF Inhibition
SZN-8141 is designed to activate Wnt signaling while inhibiting VEGF, bringing 2 therapeutic mechanisms into a single molecule.
Clinical Trials at the Summit
June 12, 2026 - June 13, 2026
Las Vegas
The 2026 Clinical Trials at the Summit meeting will be held June 12-13 at the Fontainebleau Hotel in Las Vegas, featuring presentations of new clinical trial data, expert panel discussions, and perspectives from leaders across the retina, biotechnology, regulatory, and investment communities.
Related Content
June 24, 2026
Five-Year Insights From the Pegcetacoplan Program
Lawrence J. Singerman, MD, FACS, reflects on clinical insights from the OAKS, DERBY, and GALE studies in geographic atrophy.
June 24, 2026
Biogen Signals Long-Term Commitment to Retina
At Clinical Trials at the Summit, industry veteran Anthony Wallace discussed how collaboration between biotech companies, pharmaceutical firms, and retina specialists drives innovation.
June 24, 2026
Getting Started in Clinical Trials
Deepak Sambhara, MD, FASRS, says aspiring investigators should seek mentorship, build relationships, and stay curious as they pursue opportunities in clinical research.
June 24, 2026
Migaldendranib Shows Substantial Injection Reduction
Early phase 2 data in DME and nAMD showed approximately 80% reduction in intravitreal injection burden compared with pre-study treatment.
June 23, 2026
Can ROP Be Prevented?
The phase 1b tROPhy-1 study is evaluating FLQ-101, an investigational therapy designed to intervene before severe disease develops.
June 23, 2026
A Potential First Treatment for Stargardt Disease
Data from the phase 3 DRAGON trial support tinlarebant as a treatment for the inherited retinal disorder. Belite Bio has completed a rolling NDA submission to the FDA.
June 23, 2026
OLN-324 Shows Extended Drying in DME
In the JADE trial, the investigational bispecific agent demonstrated a faster and more durable anatomic response than faricimab. Phase 3 trials are expected to begin later this year.
June 18, 2026
Four-Year OPTIC Data Highlight Durability of Ixo-vec
Carl Danzig, MD, reviews long-term outcomes from the OPTIC trial, including an 86% annualized reduction in anti-VEGF injections through year 4.
June 18, 2026
ELARA Data Support Monthly Aflibercept 8 mg in Refractory nAMD and DME
Dilsher S. Dhoot, MD, FASRS, presents ELARA findings in previously treated patients with neovascular AMD and diabetic macular edema.
June 18, 2026
NEW DAY: Sustained-Release Steroid vs Anti-VEGF Therapy
Michael A. Singer, MD, presents data comparing a sustained-release fluocinolone acetonide implant with aflibercept in patients with retinal vascular disease.
June 18, 2026
In RVO, Aflibercept 8 mg Outcomes Unaffected by Baseline CRT
A post hoc analysis of QUASAR data, presented at Clinical Trials at the Summit, finds consistent visual and anatomic results across retinal vein occlusion subtypes.
June 18, 2026
Real-World Findings Reinforce Encelto’s Role in MacTel Treatment
Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.
June 17, 2026
How to Choose the Right CRO
During a panel discussion at Clinical Trials at the Summit, representatives of sponsors and CROs discussed experience, staffing, costs, and the factors that drive trial performance.
June 17, 2026
LensOne Heads Toward Pivotal Trial
At Clinical Trials at the Summit 2026, Frank Brodie, MD, MBA, reviewed clinical findings for the prosthetic capsular bag and outlined plans for the GOLDEN GATE study.
June 17, 2026
SPECTRA Data Support 4D-150 in DME
Anat Loewenstein, MD, MHA, discusses previously presented findings from the SPECTRA trial at Clinical Trials at the Summit 2026.
June 16, 2026
FDA Veteran Shares Insights on Trial Design and Endpoints
Former FDA ophthalmology leader Wiley A. Chambers, MD, discusses pivotal studies, safety databases, and regulatory expectations for retinal therapies.
June 4, 2026
CTS 2026: What to Expect in Las Vegas
Arshad M. Khanani, MD, previews this year’s Clinical Trials at the Summit meeting, highlighting new clinical trial data, expert panels discussing a variety of topics, and a keynote by the former director of the FDA’s ophthalmic devices division.